Pharmaceutical Technology
Search documents
NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference
Globenewswire· 2025-07-31 12:15
Core Insights - NetraMark Holdings Inc. is participating in the 45th Annual Growth Conference hosted by Canaccord Genuity from August 12-14, 2025, in Boston, Massachusetts, where CEO George Achilleos will engage with institutional investors and strategic partners [1][2][4] Company Overview - NetraMark is focused on transforming clinical development through its AI platform, NetraAI, which extracts clinically relevant insights from complex datasets to identify patient subpopulations, mitigate placebo effects, and improve patient selection strategies [3][5] - The company's technology utilizes a novel topology-based algorithm that allows for effective segmentation of patient data, enabling the application of various machine learning methods to enhance drug response analysis and treatment efficacy [5] Conference Participation - The conference serves as a networking venue for innovative growth companies and institutional investors, providing opportunities for strategic collaboration and showcasing new technology platforms [2] - George Achilleos will be available for one-on-one meetings to discuss the application of NetraMark's AI platform across therapeutic areas and its role in supporting precision medicine strategies [4]
NetraMark to Attend Canaccord Genuity's 45th Annual Growth Conference
GlobeNewswire News Room· 2025-07-31 12:15
Core Insights - NetraMark Holdings Inc. is participating in the 45th Annual Growth Conference hosted by Canaccord Genuity from August 12-14, 2025, in Boston, Massachusetts, where CEO George Achilleos will engage with institutional investors and strategic partners [1][2][4] Company Overview - NetraMark is focused on transforming clinical development through its AI platform, NetraAI, which extracts clinically relevant insights from complex datasets to identify patient subpopulations, mitigate placebo effects, and improve patient selection strategies [3][5] - The company's technology allows for the segmentation of diseases and classification of patients based on their sensitivity to drugs and treatment efficacy, utilizing a novel topology-based algorithm [5] Conference Participation - The conference serves as a networking venue for innovative growth companies and institutional investors, providing opportunities for strategic collaboration and showcasing new technology platforms [2] - George Achilleos will be available for one-on-one meetings to discuss the application of NetraMark's AI platform across various therapeutic areas [4]